Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab in untreated HCC
NCT03434379Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2018
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of atezolizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Mar 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03434379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434379.